miR-210高表达与乳腺癌预后关系的meta分析

目的:探讨miR-210高表达与乳腺癌患者预后的关系?方法:检索PubMed?EMBASE?Web of Science和CNKI等数据库中关于miR-210高表达与乳腺癌预后关系的文献资料,按纳入标准筛选出相关文献,提取总生存率 (overall survival,OS)?无复发生存率(recurrence-free survival,RFS)和无病生存率(disease-free survival,DFS)的风险比(hazard ratio,HR)及其95%可信区间(CI),用Stata软件进行分析合并?结果:按标准共纳入文献6篇,病例数585例,meta分析显示:和低表达组相比,miR-210高表达组OS的合并HR值为2.29(95%CI:0.89~5.91,P=0.086);miR-210高表达组DFS/RFS的合并HR值为2.81(95%CI:1.35~5.87,P=0.006)?结论:以现有相关研究结果的meta分析显示,miR-210的高表达是乳腺癌临床预后的不良因素?

Prognostic value of miR-210 in breast cancer:A meta-analysis

Objective:To summarize the predicting role of increased miR-210 expression for survival in patients with breast cancer. Methods:All of relevant studies were identified by searching PubMed,EMBASE,Web of Science and CNKI. Pooled hazard ratios(HRs)with 95% confidence intervals(CIs) for overall survival(OS),recurrence-free survival(RFS),and disease-free survival(DFS)were calculated by Stata 12.0 software. Results:A total of 585 cases from 6 eligible studies were involved for this global meta-analysis. For OS,the pooled HR of higher miR-210 expression in breast cancer was 2.29(95%CI:0.89~5.91,P= 0.086). And for DFS/RFS,the pooled HR of higher miR-210 expression in breast cancer was 2.81(95%CI:1.35~5.87,P=0.006). Conclusion:This meta-analysis suggests that high expression of miR-210 may predict poor survival in patients with breast cancer.